Gayatri Digambar: Safe Anticoagulation Conversion
Gayatri Digambar, B.Pharm Finalist and Registered Pharmacist, posted on LinkedIn:
”Anticoagulation Conversion
Mastering the Transition: Ensuring Patient Safety in Complex Drug Therapy
As Registered Pharmacists, managing anticoagulation therapy transitions (bridging) is one of our most critical clinical responsibilities. The precision of these conversions directly impacts patient outcomes and minimizes the risk of bleeding or clotting.
Sharing a look at the key protocols for safely converting between different anticoagulants:
Bridging from Heparin/LMWH to Warfarin: This requires a careful overlap period until the INR is consistently in the therapeutic range (>2 for at least 2 days).
Transitioning to DOACs (Dabigatran, Rivaroxaban, Apixaban): Exact timing is crucial. For instance, stop IV heparin immediately and start the DOAC within 0–2 hours of the next scheduled LMWH dose to maintain anticoagulation continuity.
Warfarin Management: When switching from warfarin to a DOAC, the INR must be checked and confirmed to be <2 before initiating the new agent.
This attention to detail is vital for clinical excellence and regulatory compliance.”

Stay updated with Hemostasis Today.
-
May 28, 2026, 12:57Ahmed Kardousha: Protecting Growth and Fertility in Transfusion-Dependent β-Thalassemia
-
May 28, 2026, 12:36Kabilan K L: Key Nursing Considerations for Abciximab Therapy
-
May 28, 2026, 12:17Astha Thakkar: Practical Approaches to Platelet Thresholds in ITP
-
May 28, 2026, 09:16Maxime Dely: The Human Connection Behind Stem Cell Donation
-
May 28, 2026, 09:15Heghine Khachatryan: Maternal Health Begins With Recognizing Iron Deficiency Early
-
May 28, 2026, 09:15Alejandro González Veliz: Why Cardiovascular Prevention Matters More Than Intervention
-
May 28, 2026, 05:29Kidist K.: First Balloon Pulmonary Angioplasty Performed as New CTEPH Program Launches
-
May 28, 2026, 04:59Maria Sol Andres: Exploring Lipid Disorders in Modern Cancer Care
-
May 28, 2026, 04:42Francesca Granata: Representing the Porphyria Community at the 79th World Health Assembly